Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02504528
Other study ID # GIRD201534
Secondary ID BAPT201534
Status Completed
Phase N/A
First received July 8, 2015
Last updated February 14, 2018
Start date July 1, 2015
Est. completion date February 1, 2018

Study information

Verified date February 2018
Source Guangzhou Institute of Respiratory Disease
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to establish the methodology of bronchial provocation tests with house dust mites in China, and to evaluate its safety and effects on upper and lower airways inflammation.


Description:

After screening,each participant undergo baseline lung function test,airway inflammation evaluation (blood and sputum eosinophils count,interleukin-13 (IL-13),FeNO)and airway responsiveness tests(methacholine bronchial provocation,nasal histamine provocation).

On the second day,the participant undergo bronchial house dust mites challenge tests.

On the third day,the participant undergo the lung function test,airway inflammation evaluation (blood and sputum eosinophils count,IL-13,FeNO)and airway responsiveness tests(methacholine bronchial provocation,nasal histamine provocation).


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date February 1, 2018
Est. primary completion date July 1, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Clinical diagnosis of asthma;

- Sensitive to house dust mite;

- Stable for more than 4 weeks with FEV1=70%pred

Exclusion Criteria:

- exacerbation within 3 months;

- upper airway infections within 6 weeks;

- concomitant of hypertension or heart diseases;

- pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Other:
house dust mites
house dust mites(two-fold increasing concentration of house dust mite (HDM) extract, dilutions prepared starting from 1:8, 1:16, 1:32, 1:64, 1:128, 1: 256, 1:512, 1:1024,……)

Locations

Country Name City State
China Guangzhou institute of respiratory disease Guangzhou Guangdong

Sponsors (2)

Lead Sponsor Collaborator
Guangzhou Institute of Respiratory Disease Firestone Institute for Respiratory Health

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other correlate of IL-4,IL-13,periostin with provocative concentration induced a 20% decrease in FEV1 to house dust mite in asthmatic By Comparison with methacholine provocation test 30 mins and 24 hours after house dust mites bronchial challenge
Other Incidence and Severity of Adverse Events During The House Dust Mite Bronchial Provocation Test By Comparison with methacholine provocation test at 30 min and 24 hours after challenge test. 30 minutes, 7 hours and 24 hours after house dust mites bronchial provocation
Primary percentages of the participants that tested positive to house dust mites bronchial provocation 30 minutes after house dust mites bronchial provocation
Secondary Changes of the percentages of eosinophils in sputum, nasal lavage and fractional exhaled nitric oxide (FeNO) from baseline 30mins, 7 and 24 hours after bronchial challenge
Secondary Changes of provocative concentration induced a 20% decrease in forced expiratory volume at one second (FEV1) to methacholine before and after house dust mites bronchial provocation 24 hours after house dust mites bronchial challenge
Secondary percentages of the participants that tested positive to house dust mites bronchial provocation measured by impulse oscillometry 10 minutes after house dust mites bronchial provocation
Secondary Changes of provocative concentration induced a 60% increase in nasal airway resistance to histamine before and after house dust mites bronchial provocation By Comparison with methacholine provocation test 24 hours after house dust mites bronchial challenge
See also
  Status Clinical Trial Phase
Completed NCT03850626 - Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients
Completed NCT02911688 - Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure Phase 2
Active, not recruiting NCT01776177 - The REALITY Study - a Real-life Long-term Analysis of Xolair Therapy N/A
Completed NCT00485576 - Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma Phase 2
Completed NCT00736801 - Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma N/A
Completed NCT00515775 - Influence of a Inhaled Corticosteroid Therapy Versus Corticosteroid + LABA Therapy on the FeNO of Asthmatic Children N/A
Completed NCT04259164 - Anti-inflammatory Effects Glycopyrronium Phase 3
Active, not recruiting NCT04619017 - Airway Immune Response to Allergens (Use Lay Language Here) Phase 1
Completed NCT01699594 - Change in Airway Responsiveness After Allergen Exposure N/A
Completed NCT00999466 - The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen Phase 2
Completed NCT01353755 - 2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma Phase 3
Completed NCT00434434 - A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma Phase 2
Completed NCT00492076 - Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma Phase 4
Completed NCT00829179 - Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma Phase 3
Completed NCT00490425 - Prevention of Asthma and Allergy by Probiotic Lactobacillus GG Phase 4
Recruiting NCT04542902 - Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma N/A
Recruiting NCT04109534 - Effect of a Dietary Fatty Acid Supplementation on Symptoms and Bronchial Inflammation in Patients With Asthma N/A
Active, not recruiting NCT05186025 - Tyrosine Allergoid Paediatric and Adult Study
Withdrawn NCT03307278 - House Dust Mite Induced Inflammasome Activation on Corticosteroid Resistance N/A
Enrolling by invitation NCT06151938 - Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis